Clinical Trial Update: Efficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/MGD/Blepharitis [Phase 4]

View source ↗

Summary

Phase 4 clinical trial comparing Zylet (tobramycin + loteprednol etabonate) to Lotemax for ocular surface inflammation associated with Meibomian Gland Dysfuncti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meibomian Gland Dysfunction
• Posterior Blepharitis

Drugs mentioned

• Lotemax (Loteprednol etabonate)
• Zylet (loteprednol etabonate and tobramycin)

Snippet

Sponsor: Massachusetts Eye and Ear Infirmary | Conditions: Meibomian Gland Dysfunction, Posterior Blepharitis | Phase 4 | Status: COMPLETED | Results posted: 2017-06-19